Document is current
Any future updates will be listed below
-
Authors
Di Donato, Marzia
Cristiani, Costanza Maria
Capone, Mariaelena https://orcid.org/0000-0002-1352-2532
Garofalo, Cinzia
Madonna, Gabriele https://orcid.org/0000-0001-9395-3190
Passacatini, Lucia Carmela
Ottaviano, Margaret
Ascierto, Paolo Antonio
Auricchio, Ferdinando
Carbone, Ennio
Migliaccio, Antimo https://orcid.org/0000-0002-4197-2055
Castoria, Gabriella https://orcid.org/0000-0002-0576-4494
- License Information
-
More Information
Article History
Received: 22 April 2024
Revised: 18 December 2024
Accepted: 14 January 2025
First Online: 21 January 2025
Competing interests
: PAA Stock and Other Ownership Interests: PrimeVax Consulting or Advisory Role: Bristol Myers Squibb, Roche/Genentech, Merck Sharp & Dohme, Novartis, Array BioPharma, Merck Serono, Pierre Fabre, Incyte, MedImmune, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Takis Biotech, Lunaphore Technologies, Seattle Genetics, ITeos Therapeutics, Medicenna, Bio-Al Health, ValoTx, Replimune, Bayer Research Funding: Bristol Myers Squibb (Inst), Roche/Genentech (Inst), Array BioPharma (Inst), Sanofi (Inst), Pfizer (Inst) Travel, Accommodations, Expenses: Merck Sharp & Dohme, Pfizer, Bio-Al Health, Replimune. The other authors declare no conflict of interest.
: All methods were performed in accordance with the relevant guidelines and regulations. The Ethics Committee of National Cancer Institute—I.R.C.C.S.—Fondazione “G. Pascale”, Napoli, (Italy), approved the study (Protocol No. 33/17oss). Informed consent was obtained from all patients for experimentation in human subjects.
